Cover Image
Market Research Report

United States Generic Drugs Market, By Therapeutic Application (CNS, Cardiovascular, Dermatology, Oncology, GU, Respiratory, Anti-infective & Others], Companies

Published by Renub Research Product code 652216
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
United States Generic Drugs Market, By Therapeutic Application (CNS, Cardiovascular, Dermatology, Oncology, GU, Respiratory, Anti-infective & Others], Companies
Published: June 8, 2018 Content info: 120 Pages
Description

United States Generic Drugs Market is projected to exceed USD 210 Billion by 2024 . United States Generic Drugs Market is so huge that nearly 80% of dispensing prescriptions accounts generic drugs. According to FDA in the United States 9 out of 10 prescriptions filled are for generic drugs . Most of the physicians and hospitals are now prescribing generic drugs than that of the brand-name drugs. Generic Drugs are those drugs which have same active component as patent drugs in same outline & equal amounts. Generic drugs are also called as Off-Label drugs.

The prime reason for the growth of United States Generic Drugs Market can be attributed to its pricing, on an average generic (Off-Label) drug is around 40-60% cheaper than those of Branded Drugs. However, this price of generic drug further declines, when various generic drug companies target a single approved drug, then market competition results in prices 85% less than the branded drugs. Also, increasing number of drug patent expirations, government initiatives and rising prevalence of chronic diseases are some other factors which are expected to propel the growth of United States Generic Drugs Market in the near future.

Renub Research report titled "United States Generic Drugs Market, By Therapeutic Application [Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU)/Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others], Companies (Teva, Mylan N.V., Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy's, Sun Pharma, & Others) " provides a complete analysis of US Generic Drugs Market.

image1

Therapeutic Application - Oncology Generic Drug Market is likely to witness a Significant Growth during the Forecast Period

The report studies the market of the following Therapeutic Application segments: Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU) / Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others. Central Nervous System (CNS), Cardiovascular, Respiratory and Oncology are some of the segments that will attract the attention of generic drugs market participants.

All companies in this report has been covered with following view points

  • 1. Company Strategy
  • 2. Sales

Companies Analysis

Teva, Mylan, Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy's, Sun Pharma are some of the top companies operating in the United States Generic Drug Market; which has been studied thoroughly in the report.

By Therapeutic Application:

  • Central Nervous System (CNS)
  • Cardiovascular
  • Dermatology
  • Genitourinary (GU)/Harmonal Drugs
  • Respiratory
  • Anti-infective
  • Oncology
  • Others

Key Companies Covered in the Report:

  • Teva
  • Mylan N.V.
  • Sandoz
  • Endo Pharmaceuticals
  • Lupin Limited
  • Dr Reddy's
  • Sun Pharma
  • Others
Table of Contents

Table of Contents

1. Executive Summary

2. United States Pharmaceutical Market

  • 2.1 Branded Pharmaceutical Market
  • 2.2 Generics Pharmaceutical Market

3. United States Generic Drugs Saving

4. Market Share - United States Pharmaceutical

  • 4.1 Branded vs. Generics Drugs
  • 4.2 Branded Generic vs. Unbranded Generic Drug
  • 4.3 Volume Penetration - Generic vs. Branded Drugs
  • 4.4 Therapeutic Application

5. United States Generic Drugs Market (2010 - 2024)

  • 5.1 Branded Generic Drugs Market
  • 5.2 Unbranded Generic Drugs Market

6. Therapeutic Application - United States Generic Drugs Market (2010 - 2024)

  • 6.1 Central Nervous System (CNS)
  • 6.2 Cardiovascular
  • 6.3 Dermatology
  • 6.4 Genitourinary / Hormonal Drugs
  • 6.5 Respiratory
  • 6.6 Anti-infective
  • 6.7 Oncology
  • 6.8 Others

7. Teva Pharmaceutical Industries Ltd - Company Analysis

  • 7.1 Product Launch
    • 7.1.1 Point No. 1
    • 7.1.2 Point No. 2
    • 7.1.3 Point No. 3
    • 7.1.4 Point No. 4
    • 7.1.5 Point No. 5
    • 7.1.6 Point No. 6
  • 7.2 Financial Insight

8. Mylan N.V. - Company Analysis

  • 8.1 Product Launch
    • 8.1.1 Point No. 1
    • 8.1.2 Point No. 2
    • 8.1.3 Point No. 3
    • 8.1.4 Point No. 4
    • 8.1.5 Point No. 5
    • 8.1.6 Point No. 6
  • 8.2 Financial Insight

9. Sandoz Inc. - Company Analysis

  • 9.1 Product Launch
    • 9.1.1 Point No. 1
    • 9.1.2 Point No. 2
  • 9.2 Financial Insight

10. Endo Pharmaceuticals - Company Analysis

  • 10.1 Product Launch
    • 10.1.1 Point No. 1
    • 10.1.2 Point No. 2
    • 10.1.3 Point No. 3
    • 10.1.4 Point No. 4
  • 10.2 Financial Insight

11. Lupin Limited - Company Analysis

  • 11.1 Product Launch
    • 11.1.1 Point No. 1
    • 11.1.2 Point No. 2
    • 11.1.3 Point No. 3
    • 11.1.4 Point No. 4
    • 11.1.5 Point No. 5
    • 11.1.6 Point No. 6
    • 11.1.7 Point No. 7
  • 11.2 Financial Insight

12. Dr Reddy's - Company Analysis

  • 12.1 Business Portfolio
    • 12.1.1 Point No. 1
    • 12.1.2 Point No. 2
    • 12.1.3 Point No. 3
  • 12.2 Financial Insight

13. Sun Pharmaceutical Industries Ltd. - Company Analysis

  • 13.1 Product Launch
    • 13.1.1 Point No. 1
    • 13.1.2 Point No. 2
    • 13.1.3 Point No. 3
    • 13.1.4 Point No. 4
  • 13.2 Financial Insight

14. Others

  • 14.1 Financial Insight

15. Growth Driver

  • 15.1 Rising Geriatric Population of United States
  • 15.2 Generic Drugs Cost less than Brand Name Drugs
  • 15.3 Rising Incidence of non-communicable Diseases

16. Challenges

  • 16.1 Lack of Regulation & Information
  • 16.2 Long Halt for Expiration of Patent Drug

List of Figures:

  • Figure 2 1: US Pharma Market (Billion US$), 2010 - 2017
  • Figure 2 2: Forecast for US Pharma Market (Billion US$), 2018 - 2024
  • Figure 2 3: US Branded Pharma Market (Billion US$), 2010 - 2017
  • Figure 2 4: Forecast for US Branded Pharma Market (Billion US$), 2018 - 2024
  • Figure 2 5: US Generics Pharma Market (Billion US$), 2010 - 2017
  • Figure 2 6: Forecast for US Generics Pharma Market (Billion US$), 2018 - 2024
  • Figure 3 1: Savings from Generics in (Billions US$), - 2016
  • Figure 3 2: US Generic Saving (Billion US$), 2010 - 2017
  • Figure 3 3: Forecast for US Generic Saving (Billion US$), 2018 - 2024
  • Figure 4 1: US Pharmaceutical Market Share (%), 2010 - 2017
  • Figure 4 2: Forecast for US Pharmaceutical Market Share (%), 2018 - 2024
  • Figure 4 3: Generic Drug Market Share (%), 2010 - 2017
  • Figure 4 4: Forecast for Generic Drug Market Share (%), 2018 - 2024
  • Figure 4 5: US Generic V.S. Branded Drug Volume Penetration (%), 2010 - 2017
  • Figure 4 6: Forecast for US Generic V.S. Branded Drug Volume Penetration (%), 2018 - 2024
  • Figure 4 7: US Generic Drugs - By Therapeutic Application Market Share (%), 2010 - 2017
  • Figure 4 8: Forecast for US Generic Drugs - By Therapeutic Application Market Share (%), 2018 - 2024
  • Figure 5 1: Branded Generic Drug Market (Billion US$), 2010 - 2017
  • Figure 5 2: Forecast for Branded Generic Drug Market (Billion US$), 2018 - 2024
  • Figure 5 3: Unbranded Generic Drug Market (Billion US$), 2010 - 2017
  • Figure 5 4: Forecast for Unbranded Generic Drug Market (Billion US$), 2018 - 2024
  • Figure 6 1: Central Nervous System Market (Billion US$), 2010 - 2017
  • Figure 6 2: Forecast for Central Nervous System Market (Billion US$), 2018 - 2024
  • Figure 6 3: U.S Incidence of cardiovascular disease by age and sex -2013
  • Figure 6 4: Cardiovascular Market (Billion US$), 2010 - 2017
  • Figure 6 5: Forecast for Cardiovascular Market (Billion US$), 2018 - 2024
  • Figure 6 6: Skin Diseases Prevalence in US - 2013
  • Figure 6 7: Dermatology Market (Million US$), 2010 - 2017
  • Figure 6 8: Forecast for Dermatology Market (Million US$), 2018 - 2024
  • Figure 6 9: Genitourinary/Hormonal Drugs Market (Billion US$), 2010 - 2017
  • Figure 6 10: Forecast for Genitourinary/Hormonal Drugs Market (Billion US$), 2018 - 2024
  • Figure 6 11: Respiratory Market (Billion US$), 2010 - 2017
  • Figure 6 12: Forecast for Respiratory Market (Billion US$), 2018 - 2024
  • Figure 6 13: Anti-infective Market (Billion US$), 2010 - 2017
  • Figure 6 14: Forecast for Anti-infective Market (Billion US$), 2018 - 2024
  • Figure 6 15: Oncology Market (Billion US$), 2010 - 2017
  • Figure 6 16: Forecast for Oncology Market (Billion US$), 2018 - 2024
  • Figure 6 17: Others Market (Billion US$), 2010 - 2017
  • Figure 6 18: Forecast for Others Market (Billion US$), 2018 - 2024
  • Figure 7 1: Teva - US Generic Drugs Market (Million US$), 2011 - 2017
  • Figure 7 2: Forecast for Teva - US Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 8 1: Mylan NV - US Generic Drugs Market (Million US$), 2011 - 2017
  • Figure 8 2: Forecast for Mylan NV - US Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 9 1: Sandoz - US Generic Drugs Market (Million US$), 2011 - 2017
  • Figure 9 2: Forecast for Sandoz - US Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 10 1: Endo Pharmaceuticals - US Generic Drugs Market (Million US$), 2012 - 2017
  • Figure 10 2: Forecast for Endo Pharmaceuticals - US Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 11 1: Lupin Limited - US Generic Drugs Market (Million US$), 2011 - 2017
  • Figure 11 2: Forecast for Lupin Limited - US Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 12 1: Dr Reddy's - North America (US & Canada) Generic Drugs Market (Million US$), 2011 - 2017
  • Figure 12 2: Forecast for Dr Reddy's - North America (US & Canada) Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 13 1: Sun Pharma -US Generic Drugs Market (Million US$), 2011 - 2017
  • Figure 13 2: Forecast for Sun Pharma -US Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 14 1: Others - US Generic Drugs Market (Million US$), 2011 - 2017
  • Figure 14 2: Forecast for Others -US Generic Drugs Market (Million US$), 2018 - 2024
  • Figure 15 1: United States - Rising Geriatric Population (Million), 2000, 2016 & 2060

List of Tables:

  • Table 3-1: Top 10 Generic Drugs Ranked by Savings in US - 2016
  • Table 3-2: Ten Major US State Generic Saving in - 2016
  • Table 6-1: The Full Burden of 24 Skin Disease categories
Back to Top